**Supporting table 1a sensitivity analysis with England included in no consent group.**

|  |  |  |  |
| --- | --- | --- | --- |
| **UNADJUSTED** |  |  |  |
|  | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0.69 | 0.63-0.75 | <0.0001 |
| **ADJUSTED Cox 1** |  |  |  |
|  | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0.72 | 0.66-0.80 | 0.0001 |
|  |  |  |  |
| **IPW weighted Cox model 1** |  |  |  |
|  | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0.74 | 0.68-0.82 | 0.0001 |
|  |  |  |  |
| **Propensity score weighting 1** | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0.74 | 0.67-0.81 | 0.0001 |
| Mechanical ventilation | 0.96 | 0.88-1.1 | 0.68 |
| Vasoactive drugs | 0.79 | 0.72-0.85 | <0.0001 |
| Renal replacement | 0.83 | 0.68-1.01 | 0.0627 |
| Limitation of care | 1.02 | 0.92-1.1 | 0.68 |

1 including variables age, gender, habitat, frailty, reason for ICU admission and SOFA score

**Supporting table 1 b Sensitivity analysis with England included in consent group**

|  |  |  |  |
| --- | --- | --- | --- |
| **UNADJUSTED** |  |  |  |
|  | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0.72 | 0.66-0.79 | <0.0001 |
| **ADJUSTED Cox 1** |  |  |  |
|  | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0.95 | 0,87-1.06 | 0.30823 |
|  |  |  |  |
| **IPW weighted Cox model 1** |  |  |  |
|  | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0,95 | 0.87-1.06 | 0.429 |
|  |  |  |  |
| **Propensity score weighting 1** | HR consent vs no consent | 95% CI | P-value |
| Overall survival | 0.92 | 0.83-1.02 | 0.107 |
| Mechanical ventilation | 0.8 | 0.72-0.88 | <0.0001 |
| Vasoactive drugs | 0.73 | 0.66-0.80 | <0.0001 |
| Renal replacement | 0.94 | 0.76-1.16 | 0.57 |
| Limitation of care | 1.06 | 0.93-1.2 | 0.351 |

1 including variables age, gender, habitat, frailty, reason for ICU admission and SOFA score